Follow
Notice to attend Extraordinary General Meeting in Umecrine Cognition AB
07 July 2022 - 12:00
The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the extraordinary general meeting at 10:00 a.m. on Wednesday 10 August 2022. The meeting will be held through postal voting only.
Aktieägarna i Umecrine Cognition AB, org.nr 556698-3655, kallas härmed till extra bolagsstämma klockan 10.00 onsdagen den 10 augusti 2022. Stämman kommer att hållas enbart genom poströstning.
The complete Notice can be found on /Kallelsen i sin helhet finns på sidan:
www.umecrinecognition.com/en/investors/corporate-governance/extra-general-meeting-august-2022/
Provided by: MFN
Umecrine Cognition AB
Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (neurosteroids)....
Learn more about company